Under construction – not a live service
Sign in
Taking people in IrelandPhase 3

Comparing NXT007 with emicizumab for people with hemophilia A

Tests NXT007 against emicizumab to prevent bleeding in people with hemophilia A.

Key facts

Who runs it
Hoffmann-La Roche
Where
Dublin 12 and Dublin 8, IrelandSee the 2 sitesAlso in 23 other countries, 71 sites
Registry title
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Status
Recruiting
Phase
Phase 3
People taking part
360 people, planned
Started
27 Apr 2026
Expected to end
29 Jan 2032
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • NXT007
  • Emicizumab
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 12 and older with hemophilia A, with or without FVIII inhibitors. It compares NXT007 with emicizumab.

Age
12 years and older
Sex
All sexes
Disease stage
Severe or moderate congenital hemophilia A, with or without FVIII inhibitors. Mild congenital hemophilia A only with chronic FVIII inhibitors.
Earlier treatment
Details of past FVIII, bypassing agent and emicizumab treatment and bleeding episodes must be documented for at least the last 6 months. People on on-demand treatment must agree to move to prophylaxis with emicizumab or NXT007.
Biomarker or test result
Severe: FVIII:C <1 IU/dL. Moderate: FVIII:C between ≥1 IU/dL and ≤5 IU/dL. Mild: FVIII:C between >5 IU/dL and <40 IU/dL, with chronic FVIII inhibitors and baseline FVIII:C <5 IU/dL for ≥12 months. Documented FVIII inhibitor test results from the past 12 months are needed.

Main reasons for not taking part

  • Allergy or sensitivity to the study drugs or their components
  • Use of systemic immunomodulators such as interferon or rituximab, except HIV antiretroviral therapy
  • Refusal of plasma-derived or blood product transfusion in an emergency
  • Planned surgery during the study, other than minor procedures
  • History of ventricular rhythm problems, certain heart disease, a clinically significant abnormal ECG, or prior heart attack

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Diagnosis of severe (FVIII:C <1 International Unit per decilitre [IU/dL]) or moderate (FVIII:C between ≥1 IU/dL and ≤5 IU/dL) congenital hemophilia A with or without inhibitors against FVIII
  • Diagnosis of mild (FVIII:C between >5 IU/dL and <40 IU/dL) congenital hemophilia A with chronic FVIII inhibitors, defined as documented FVIII inhibitor ( ≥0.6 BU/mL or ≥1.0 BU/mL only for laboratories with a historical sensitivity cutoff for inhibitor detection of 1.0 BU/mL) and chronic reduction of endogenous baseline FVIII:C to <5 IU/dL for ≥12 months
  • Documented historical FVIII inhibitor assay results within the 12 months prior to enrollment
  • Documentation of the details of prophylactic and episodic FVIII treatment, bypassing agent (BPA) treatment, emicizumab prophylaxis treatment, and the number and type of bleeding episodes for at least the last 6 months prior to screening
  • For potential participants taking on-demand treatments prior to study entry: agreement to move to a prophylaxis treatment with either emicizumab or NXT007, according to assigned randomization

Who cannot take part

  • Planned surgery (excluding minor procedures, such as non-molar tooth extraction or incision and drainage) during the study
  • History or presence of an abnormal ECG that is deemed clinically significant, (e.g., complete left bundle branch block, second- or third-degree atrioventricular heart block) or evidence or clinical history of prior myocardial infarction
  • Sensitivity to any of the study investigations, or components thereof, or drug or other allergy that, in the opinion of the investigator, contraindicates participation in the study
  • Use of systemic immunomodulators (e.g., interferon or rituximab) at the time of enrollment or planned use during the study, except for antiretroviral therapy to treat HIV
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing)
  • Refusal to accept plasma-derived and/or blood product transfusion support in an emergency scenario

Where in Ireland

Also in 23 other countries, 71 sites

  • Children's Health IrelandDublin 12, IrelandTaking people
  • St James's HospitalDublin 8, IrelandTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors.

The 3 groups in the trial

  • Main Study Treatment Period: NXT007 ProphylaxisTreatment being tested

    Participants randomized to this arm will receive NXT007 prophylaxis for the main study treatment period.

    Treatment: NXT007

  • Main Study Treatment Period: Emicizumab ProphylaxisExisting treatment, for comparison

    Participants randomized to this arm will receive emicizumab prophylaxis for the main study treatment period at 3 mg/kg once weekly (QW) for 4 weeks as loading doses, followed by maintenance dosing of either 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W). Loading doses are not required for participants who were taking emicizumab prior to study start.

    Treatment: Emicizumab

  • Open-Label Extension Period: NXT007 ProphylaxisTreatment being tested

    After the main study treatment period, participants in the NXT007 arm will be able to continue with NXT007 dosing, and participants in the Emicizumab arm will be able to switch to NXT007, in the open-label extension period.

    Treatment: NXT007

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis Versus Emicizumab Prophylaxis in People With Hemophilia A
Plain-language title
Comparing NXT007 with emicizumab for people with hemophilia AGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 November 2026